These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Clinical and MRI phenotype of children with MOG antibodies. Fernandez-Carbonell C; Vargas-Lowy D; Musallam A; Healy B; McLaughlin K; Wucherpfennig KW; Chitnis T Mult Scler; 2016 Feb; 22(2):174-84. PubMed ID: 26041801 [TBL] [Abstract][Full Text] [Related]
8. Multiple Sclerosis Is Rare in Epstein-Barr Virus-Seronegative Children with Central Nervous System Inflammatory Demyelination. Nourbakhsh B; Cordano C; Asteggiano C; Ruprecht K; Otto C; Rutatangwa A; Lui A; Hart J; Flanagan EP; James JA; Waubant E Ann Neurol; 2021 Jun; 89(6):1234-1239. PubMed ID: 33704815 [TBL] [Abstract][Full Text] [Related]
9. Successful disease control with alemtuzumab in MOG-IgG-associated demyelinating disease with MS-phenotype. Otto F; Moser T; Feige J; Seiberl M; Bieler L; Sellner J Mult Scler Relat Disord; 2020 Jul; 42():102108. PubMed ID: 32339987 [TBL] [Abstract][Full Text] [Related]
12. An unusual case of anti-MOG CNS demyelination with concomitant mild anti-NMDAR encephalitis. Zhou J; Tan W; Tan SE; Hu J; Chen Z; Wang K J Neuroimmunol; 2018 Jul; 320():107-110. PubMed ID: 29661538 [TBL] [Abstract][Full Text] [Related]
13. Encephalitis is an important clinical component of myelin oligodendrocyte glycoprotein antibody associated demyelination: a single-center cohort study in Shanghai, China. Wang L; ZhangBao J; Zhou L; Zhang Y; Li H; Li Y; Huang Y; Wang M; Lu C; Lu J; Zhao C; Quan C Eur J Neurol; 2019 Jan; 26(1):168-174. PubMed ID: 30133068 [TBL] [Abstract][Full Text] [Related]
14. The role of myelin oligodendrocyte glycoprotein in autoimmune demyelination: a target for multiple sclerosis therapy? Lee DH; Linker RA Expert Opin Ther Targets; 2012 May; 16(5):451-62. PubMed ID: 22494461 [TBL] [Abstract][Full Text] [Related]
16. MOG-antibody-associated disease is different from MS and NMO and should be considered as a distinct disease entity - No. Cobo-Calvo A; Marignier R Mult Scler; 2020 Mar; 26(3):274-276. PubMed ID: 31842679 [No Abstract] [Full Text] [Related]
17. Perivascular enhancement in anti-MOG antibody demyelinating disease of the CNS. Komatsu T; Matsushima S; Kaneko K; Fukuda T J Neurol Neurosurg Psychiatry; 2019 Jan; 90(1):111-112. PubMed ID: 30297517 [No Abstract] [Full Text] [Related]
18. The spectrum of MOG autoantibody-associated demyelinating diseases. Reindl M; Di Pauli F; Rostásy K; Berger T Nat Rev Neurol; 2013 Aug; 9(8):455-61. PubMed ID: 23797245 [TBL] [Abstract][Full Text] [Related]
19. Relapsing optic neuritis and meningoencephalitis in a child: case report of delayed diagnosis of MOG-IgG syndrome. Zhong X; Chang Y; Tan S; Wang J; Sun X; Wu A; Peng L; Lau AY; Kermode AG; Qiu W BMC Neurol; 2019 May; 19(1):94. PubMed ID: 31072329 [TBL] [Abstract][Full Text] [Related]
20. MOG-antibody-associated disease is different from MS and NMOSD and should be considered as a distinct disease entity - Yes. Leite MI; Sato DK Mult Scler; 2020 Mar; 26(3):272-274. PubMed ID: 31842686 [No Abstract] [Full Text] [Related] [Next] [New Search]